Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24074971 | 0.82 | GRIA1 (0.52) | GRIA1NPY5RTSHRMEN1KMT2A | |
| SCHEMBL24571852 | 0.81 | GRIA1 (0.50) | GRIA1NPY5RMEN1KMT2AALDH1A1 | |
| SCHEMBL23344388 | 0.80 | GRIA1 (0.54) | GRIA1NPY5RTSHRALDH1A1GRIA4 | |
| SCHEMBL24571555 | 0.79 | GRIA1 (0.48) | GRIA1NPY5RMEN1KMT2AALDH1A1 | |
| SCHEMBL24571558 | 0.79 | GRIA1 (0.48) | GRIA1NPY5RMEN1KMT2AALDH1A1 | |
| SCHEMBL147253 | 0.79 | GRIA1 (0.62) | GRIA1NPY5RALDH1A1GRIA4 | |
| SCHEMBL19592332 | 0.78 | GRIA1 (0.52) | GRIA1NPY5RALDH1A1GRIA4 | |
| SCHEMBL24571575 | 0.78 | GRIA1 (0.52) | GRIA1NPY5RTSHRMEN1KMT2A | |
| SCHEMBL24571561 | 0.78 | GRIA1 (0.52) | GRIA1NPY5RTSHRMEN1KMT2A | |
| SCHEMBL8612225 | 0.78 | TSHR (0.43) | TSHRMAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097190-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20220340599-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220002317-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-01-06 | — | — | US | disclosed |
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | GRIA1 411/4885NPY5R 598/4885TSHR 2617/4885 |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | GRIA1 411/4885NPY5R 598/4885TSHR 2617/4885 |
| US-20220002317-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAA1 | GRIA1 597/4885NPY5R 584/4885TSHR 1538/4885 |
| US-20220340599-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAA1 | GRIA1 597/4885NPY5R 584/4885TSHR 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.